Last update 21 Nov 2024
SHR-1703
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms |
Target |
Mechanism IL-5 inhibitors(Interleukin-5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
13
Clinical Trials associated with SHR-1703A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma
评价多次皮下注射 SHR-1703 在嗜酸性粒细胞表型哮喘患者中的长期安全性、药效学特征和有效性的多中心、单臂 II 期临床研究
[Translation] A multicenter, single-arm Phase II clinical study to evaluate the long-term safety, pharmacodynamics and efficacy of multiple subcutaneous injections of SHR-1703 in patients with eosinophilic phenotype asthma
A Multicenter, Single-group Phase II Clinical Study to Evaluate the Long-term Safety, Pharmacodynamics and Efficacy of Multiple Subcutaneous Injections of SHR-1703 in Eosinophilic Asthma Patients
100 Clinical Results associated with SHR-1703
Login to view more data
100 Translational Medicine associated with SHR-1703
Login to view more data
100 Patents (Medical) associated with SHR-1703
Login to view more data
1
Literatures (Medical) associated with SHR-170302 Jul 2024Expert Opinion on Investigational Drugs
Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study
Article
Author: Fu, Meng ; Luo, Zhu ; Yang, Ling ; Fang, Yuan ; Luo, Yuan ; Shen, Kai
100 Deals associated with SHR-1703
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Eosinophilic Asthma | Phase 3 | CN | 28 Oct 2024 | |
| Churg-Strauss Syndrome | Phase 3 | CN | 16 Nov 2023 | |
| Churg-Strauss Syndrome | Phase 3 | CN | 16 Nov 2023 | |
| Asthma | Phase 2 | CN | 22 Dec 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04480762 (Pubmed) Manual  | Phase 1 | - | 42 | (imyerigwzj) = Magnitude and duration of reduction of EOS rose with increased dosing of SHR-1703. In 400 mg dose, remarkable efficacy of reducing EOS maintained up to approximately 6 months post single administration. oxmfnmjzry (cemgtykztn ) | Positive | 01 Jul 2024 | |
Placebo |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free